{"id":6260,"date":"2022-08-29T18:51:51","date_gmt":"2022-08-29T22:51:51","guid":{"rendered":"https:\/\/aafa.org\/?post_type=asthma_medicine&p=6260"},"modified":"2024-10-01T12:32:54","modified_gmt":"2024-10-01T16:32:54","slug":"fluticasone-furoate-umeclidinium-vilanterol-trelegy-ellipta","status":"publish","type":"asthma_medicine","link":"https:\/\/aafa.org\/asthma-medicine\/fluticasone-furoate-umeclidinium-vilanterol-trelegy-ellipta\/","title":{"rendered":"Fluticasone Furoate\/Umeclidinium\/Vilanterol – TRELEGY ELLIPTA"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Main Content” _builder_version=”4.17.4″ _module_preset=”default” custom_padding=”2%||2%||true|false” global_colors_info=”{}”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” admin_label=”Page Title” module_class=”tert-content q” _builder_version=”4.17.4″ _module_preset=”default” title_font=”|600|||||||” title_text_align=”left” title_text_color=”#008c99″ title_font_size=”39px” background_enable_image=”off” background_size=”contain” background_position=”center_left” module_alignment=”left” custom_margin=”||0px||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_post_title][et_pb_code admin_label=”Breadcrumbs” module_class=”bcrumb2″ _builder_version=”4.18.0″ _module_preset=”default” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”||||false|false” custom_css_main_element=”font-size:16px;||color: #008c99;” global_module=”1658″ global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Regular Content” _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#505050″ global_colors_info=”{}”]<\/p>\n

Drug Name<\/strong>: Fluticasone Furoate\/Umeclidinium\/Vilanterol<\/p>\n

Brand Name:<\/strong> TRELEGY ELLIPTA\u00ae<\/p>\n

Medicine Use:<\/strong> Long-term control<\/p>\n

Type of Medicine<\/strong>: Combination inhaled medicine<\/p>\n

Form<\/strong>: Dry powder inhaler<\/p>\n

Prescribing Info<\/strong>: https:\/\/www.trelegy.com\/<\/a><\/p>\n

Possible Side Effects:<\/strong>
Upper respiratory infection
Bronchitis
Thrush
Headache
Back pain
Flu
Sinus inflammation
Runny nose\/sore throat
Urinary tract infection<\/p>\n

You may experience other side effects if you have COPD. For more information, please see the TRELEGY ELLIPTA Prescribing Information<\/a><\/p>\n

Notes\/Resources:<\/strong>
How To Use TRELEGY ELLIPTA<\/a><\/p>\n

[\/et_pb_text][et_pb_text admin_label=”Price Cap Callout – GSK” _builder_version=”4.27.0″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ link_line_height=”1.7em” ul_line_height=”1.7em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” background_color=”#F5EDDF” custom_padding=”4%|4%|4%|4%|true|true” box_shadow_style=”preset2″ saved_tabs=”all” global_colors_info=”{}” global_module=”21497″ theme_builder_area=”post_content”]<\/p>\n

GSK will cap their inhaler prices at $35 for people who are commercially insured or uninsured no later than Jan. 1, 2025. Watch this page for more information on the coming price cap.<\/p>\n

[\/et_pb_text][et_pb_code admin_label=”Print” module_id=”print” module_class=”clearfix” _builder_version=”4.17.6″ _module_preset=”default” global_module=”5156″ saved_tabs=”all” global_colors_info=”{}”]<\/svg> Print post<\/a> [\/et_pb_code][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.17.4″ _module_preset=”default” custom_padding=”6%||||false|false” global_colors_info=”{}”][et_pb_image src=”https:\/\/aafa.org\/wp-content\/uploads\/2022\/08\/telegy-ellipta-2.png” alt=”Arnuity Inhaler” title_text=”telegy ellipta 2″ show_in_lightbox=”on” admin_label=”Picture” _builder_version=”4.25.1″ _module_preset=”default” locked=”off” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_links_to":"","_links_to_target":""},"medicine_use":[20],"type_of_medicine":[24],"class_list":["post-6260","asthma_medicine","type-asthma_medicine","status-publish","hentry","medicine_use-long-term-control","type_of_medicine-combination-inhaled-medicines"],"acf":[],"yoast_head":"\nFluticasone Furoate\/Umeclidinium\/Vilanterol - TRELEGY ELLIPTA - Asthma and Allergy Foundation of America<\/title>\n\n\n\n\n\n\n\n\n\n\n\n\t\n